Alphabet-A
GOOGL
Alphabet-C
GOOG
Tesla
TSLA
Meta Platforms
META
Apple
AAPL
US Stock MarketDetailed Quotes
SYRE Spyre Therapeutics
- 26.490
- -0.320-1.19%
Close Dec 10 16:00 ET
- 27.000
- +0.510+1.93%
Pre 06:16 ET
1.55BMarket Cap-17.66P/E (TTM)
27.240High26.150Low356.58KVolume26.720Open26.810Pre Close9.50MTurnover0.78%Turnover RatioLossP/E (Static)58.67MShares47.97052wk High9.06P/B1.21BFloat Cap15.37052wk Low--Dividend TTM45.73MShs Float318.750Historical High--Div YieldTTM4.07%Amplitude2.650Historical Low26.652Avg Price1Lot Size
Spyre Therapeutics News
JonesTrading Initiates Spyre Therapeutics at Hold
Spyre Therapeutics Analyst Ratings
JonesTrading Initiates Spyre Therapeutics(SYRE.US) With Hold Rating
Spyre Therapeutics Announces Grants of Inducement Awards
Express News | Spyre Therapeutics Inc - Interim Data for Spy002 Molecules Expected in Q2 2025
Express News | Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-Life Extended Anti-Tl1a Antibodies
Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday
Jefferies, Goldman Sachs Among Managers for Spyre Offering >SYRE
Spyre Offering Expected to Close on or About November 20 >SYRE
Spyre: Underwritten Offering of 7,275,000 Shares Priced at $27.50 Each >SYRE
Express News | Spyre Therapeutics Inc Shares Down 1.2% in Late Trade at $28.33 Following Filing for Stock Offering
Spyre Therapeutics Faces Internal Control Challenges
Spyre Therapeutics Announces Proposed $200M Public Offering Of Its Common Stock And Pre-Funded Warrants
Spyre Therapeutics | 10-Q/A: Quarterly report (Amendment)
Spyre Therapeutics | 10-K/A: Annual report (Amendment)
Express News | Spyre Therapeutics Inc - Material Weakness in Internal Control Over Financial Reporting Identified
Express News | Spyre Therapeutics Inc - Financial Statements for 2023 and Quarterly, Year-to-Date Periods Ended March 31, 2024 Should Not Be Relied Upon
Stifel Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $71
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.